-+ 0.00%
-+ 0.00%
-+ 0.00%

HBM Holdings publishes 2025 annual report

PUBT·04/28/2026 13:38:42
Listen to the news
HBM Holdings publishes 2025 annual report
  • HBM Holdings annual report for 2025 highlighted a sharp turnaround in performance, driven by out-licensing activity and expanded platform-based partnerships with multinational drugmakers.
  • Strategic collaboration with AstraZeneca signed in March 2025 broadened in November to add ADCs and T cell engagers, with deal economics outlining up to US$ 175 million near-term payments and up to US$ 4.4 billion in milestones; AstraZeneca also took a 9.15% stake for US$ 105 million.
  • Business development accelerated in December with a multi-year collaboration with Bristol Myers Squibb that could total US$ 90 million in payments and up to US$ 1.035 billion in milestones.
  • Pipeline update flagged batoclimab BLA for generalized myasthenia gravis under China regulator review; Windward Bio started Phase II asthma study for HBM9378 in July 2025.
  • Technology push centered on launch of fully human generative AI HCAb model in October 2025, positioned to shorten antibody discovery cycles and support next-generation modalities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12130976), on April 28, 2026, and is solely responsible for the information contained therein.